ALMSNasdaqPharmaceutical PreparationsFiscal year ends December 31
ALUMIS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$6.34+0.22 (+3.59%)
Close on Oct 19, 2026
- Market cap
- $809.56M
- P/E (TTM)
- –
- Dividend yield
- –
ALUMIS INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration | $1.66M | $1.74M | $1.93M | $2.07M | $2.67M | – | – | – | – | – | 100.0% | -37.7% |
| License | – | – | $0 | $0 | $0 | $17.39M | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Alumis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.